超过5%股东持股披露「修订」
Astria Therapeutics(ATXS)02-14 21:45
$Astria Therapeutics(ATXS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-000911 Act: 34 Size: 103 KB 网页链接
简介：Astria Therapeutics, Inc.于2008年6月26日在特拉华州成立，总部设在马萨诸塞州剑桥市。 该公司是一家生物制药公司，专注于新疗法的发现、开发和商业化。该公司的使命是通过改变生活的疗法，为那些受到罕见和小众过敏性和免疫性疾病影响的患者和家庭带来希望。该公司的主要候选产品是STAR-0215，这是一种潜在的同类最佳的血浆激肽释放酶单克隆抗体抑制剂，正在临床开发中，用于治疗遗传性血管性水肿或HAE，这是一种罕见的、使人衰弱并可能危及生命的疾病。根据迄今产生的数据和现有的HAE治疗情况，STAR-0215有可能成为对患者最友好的HAE慢性治疗方案。
| 今开：9.18 | 昨收：9.17 |
| 最高：9.46 | 最低：8.97 |
| 涨停价： | 跌停价： |
| 总市值：496414071 |
Astria Therapeutics(ATXS)02-14 21:45
$Astria Therapeutics(ATXS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-000911 Act: 34 Size: 103 KB 网页链接
Astria Therapeutics(ATXS)02-13 05:15
$Astria Therapeutics(ATXS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-014614 Size: 5 KB 网页链接
Astria Therapeutics(ATXS)01-31 22:05
$Astria Therapeutics(ATXS)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001104659-24-008571 Act: 33 Size: 551 KB 网页链接
Astria Therapeutics(ATXS)03-25 19:45
$Astria Therapeutics(ATXS)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-038165 Act: 34 Size: 361 KB 网页链接
Astria Therapeutics(ATXS)04-09 20:15
$Astria Therapeutics(ATXS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-045003 Size: 5 KB 网页链接
Astria Therapeutics(ATXS)04-09 20:15
$Astria Therapeutics(ATXS)$ 8-K Current report, item 5.02 Accession Number: 0001104659-24-045001 Act: 34 Size: 200 KB 网页链接
Astria Therapeutics(ATXS)03-05 06:25
$Astria Therapeutics(ATXS)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001104659-24-030539 Act: 34 Size: 535 KB 网页链接
Astria Therapeutics(ATXS)03-11 20:25
$Astria Therapeutics(ATXS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000315066-24-001672 Act: 34 Size: 8 KB 网页链接
Astria Therapeutics(ATXS)02-09 21:45
$Astria Therapeutics(ATXS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000315066-24-000979 Act: 34 Size: 8 KB 网页链接
Astria Therapeutics(ATXS)02-15 04:55
$Astria Therapeutics(ATXS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023538 Act: 34 Size: 98 KB 网页链接
Astria Therapeutics(ATXS)周四表示，其治疗遗传性血管水肿的药物已获得美国食品和药物管理局的快速通道指定。 这家总部位于波士顿的生物制药公司表示，单克隆抗体抑制剂STAR-0215目前正在1b/2期试验中进行测试。 （责任编辑：刘海美 ） 网页链接
$Astria Therapeutics(ATXS)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-24-049976 Act: 34 Size: 3 MB 网页链接
$Astria Therapeutics(ATXS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-049986 Act: 34 Size: 880 KB 网页链接
$Astria Therapeutics(ATXS)$ ARS Annual Report to Security Holders Accession Number: 0001104659-24-049991 Act: 34 Size: 4 MB 网页链接
$Astria Therapeutics(ATXS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001104659-24-045002 Size: 10 KB 网页链接
$Astria Therapeutics(ATXS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-045003 Size: 5 KB 网页链接
$Astria Therapeutics(ATXS)$ 8-K Current report, item 5.02 Accession Number: 0001104659-24-045001 Act: 34 Size: 200 KB 网页链接
$Astria Therapeutics(ATXS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-043092 Size: 9 KB 网页链接
$Astria Therapeutics(ATXS)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-002823 Act: 33 Size: 6 KB 网页链接
$Astria Therapeutics(ATXS)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-038165 Act: 34 Size: 361 KB 网页链接
$Astria Therapeutics(ATXS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000315066-24-001672 Act: 34 Size: 8 KB 网页链接